Manson et al. showed that six months of empagliflozin treatment in patients with T2DM and coronary artery disease (CAD) led to reductions in both extracellular volume (ECV) and indexed LV mass, while indexed intracellular volume and fibrosis biomarkers—such as soluble ST2 (sST2) and matrix metalloproteinase-2 (MMP-2)—remained unchanged [144]. This evidence concerns the gene MMP2 and coronary artery disorder.